% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hemminki:179731,
author = {K. Hemminki$^*$ and A. Kanerva and A. Försti$^*$ and A.
Hemminki},
title = {{C}ervical, vaginal and vulvar cancer incidence and
survival trends in {D}enmark, {F}inland, {N}orway and
{S}weden with implications to treatment.},
journal = {BMC cancer},
volume = {22},
number = {1},
issn = {1471-2407},
address = {Heidelberg},
publisher = {Springer},
reportid = {DKFZ-2022-00863},
pages = {456},
year = {2022},
abstract = {Incidence of cervical cancer has been reduced by organized
screening while for vaginal and vulvar cancers no systematic
screening has been implemented. All these cancers are
associated with human papilloma virus (HPV) infection. We
wanted to analyze incidence trends and relative survival in
these cancers with specific questions about the possible
covariation of incidence, survival changes coinciding with
incidence changes and the role of treatment in survival. We
used nationwide cancer registry data for Denmark (DK),
Finland (FI), Norway (NO) and Sweden (SE) to address these
questions.We use the NORDCAN database for the analyses:
incidence data were available from 1943 in DK, 1953 in FI
and NO and 1960 in SE, through 2016. Survival data were
available from 1967 through 2016. World standard population
was used in age standardization.In each country the
incidence of cervical cancer declined subsequent to rolling
out of screening activities. The attained plateau incidence
was lowest at 4/100,000 in FI and highest at 10/100,000 in
DK and NO. The incidence of vaginal and vulvar cancer
remained relatively constant at about 2/100,000. Relative
1-year survival in cervical cancer improved in all countries
from low $80\%s$ to high $80\%s$ in the 50-year period, and
5-year survival improved also but at $20\%$ units lower
level. Survival gains were found only in patients diagnosed
before age 60 years. Survival in vaginal and vulvar cancer
followed the same patterns but at a few $\%$ units lower
level.Cervical cancer screening appeared to have reached its
limits in the Nordic countries by year 2000. Novel
treatments, such as immunotherapy, would be needed to
improve survival until HPV vaccination will reach population
coverage and boost the global fight against these cancers.},
keywords = {Denmark: epidemiology / Early Detection of Cancer / Female
/ Finland: epidemiology / Humans / Incidence / Middle Aged /
Norway: epidemiology / Papillomavirus Infections / Sweden:
epidemiology / Uterine Cervical Neoplasms: prevention $\&$
control / Uterine Cervical Neoplasms: therapy / Vulvar
Neoplasms: epidemiology / Vulvar Neoplasms: therapy /
Age-specific incidence (Other) / Human papilloma virus
(Other) / Incidence trends (Other) / Relative survival
(Other) / Risk factors (Other)},
cin = {B062 / HD01},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:35473606},
doi = {10.1186/s12885-022-09582-5},
url = {https://inrepo02.dkfz.de/record/179731},
}